ARWR – Arrowhead Pharmaceuticals, Inc.
Float Short %
10.08
Margin Of Safety %
Put/Call OI Ratio
0.41
EPS Next Q Diff
0.85
EPS Last/This Y
4.87
EPS This/Next Y
-3.25
Price
21.32
Target Price
41.62
Analyst Recom
1.67
Performance Q
38.6
Relative Volume
1.28
Beta
0.97
Ticker: ARWR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | ARWR | 15.74 | 0.45 | 1.94 | 26942 |
| 2025-07-28 | ARWR | 16.2 | 0.46 | 0.16 | 27301 |
| 2025-07-29 | ARWR | 15.91 | 0.46 | 1.39 | 27612 |
| 2025-07-30 | ARWR | 15.7 | 0.47 | 0.46 | 27999 |
| 2025-07-31 | ARWR | 15.78 | 0.48 | 0.10 | 28419 |
| 2025-08-01 | ARWR | 15.92 | 0.48 | 0.20 | 28498 |
| 2025-08-04 | ARWR | 16.48 | 0.47 | 0.13 | 28944 |
| 2025-08-05 | ARWR | 16.47 | 0.47 | 1.95 | 29181 |
| 2025-08-06 | ARWR | 16.31 | 0.47 | 0.53 | 29304 |
| 2025-08-07 | ARWR | 16.07 | 0.47 | 0.53 | 29368 |
| 2025-08-08 | ARWR | 16.42 | 0.46 | 0.23 | 29664 |
| 2025-08-11 | ARWR | 17.21 | 0.46 | 0.20 | 30469 |
| 2025-08-12 | ARWR | 17.8 | 0.46 | 0.14 | 30598 |
| 2025-08-13 | ARWR | 19.99 | 0.45 | 0.07 | 30729 |
| 2025-08-14 | ARWR | 18.78 | 0.45 | 0.27 | 31387 |
| 2025-08-15 | ARWR | 20.51 | 0.44 | 0.06 | 32242 |
| 2025-08-18 | ARWR | 19.9 | 0.40 | 0.20 | 26808 |
| 2025-08-19 | ARWR | 19.85 | 0.40 | 1.46 | 28010 |
| 2025-08-20 | ARWR | 20.21 | 0.40 | 0.43 | 28298 |
| 2025-08-21 | ARWR | 20.75 | 0.41 | 0.25 | 28722 |
| 2025-08-22 | ARWR | 21.31 | 0.41 | 0.74 | 29249 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | ARWR | 15.74 | 20.2 | -277.9 | -0.18 |
| 2025-07-28 | ARWR | 16.23 | 20.2 | -313.5 | -0.18 |
| 2025-07-29 | ARWR | 15.92 | 20.2 | -286.3 | -0.18 |
| 2025-07-30 | ARWR | 15.70 | 20.2 | -288.3 | -0.18 |
| 2025-07-31 | ARWR | 15.80 | 20.2 | -299.3 | -0.18 |
| 2025-08-01 | ARWR | 15.93 | 20.2 | -300.5 | -0.18 |
| 2025-08-04 | ARWR | 16.47 | 20.2 | -315.4 | -0.18 |
| 2025-08-05 | ARWR | 16.47 | 20.2 | -296.1 | -0.18 |
| 2025-08-06 | ARWR | 16.30 | 20.2 | -290.2 | -0.18 |
| 2025-08-07 | ARWR | 16.06 | 20.2 | -287.4 | -0.18 |
| 2025-08-08 | ARWR | 16.42 | 20.2 | -308.4 | -0.20 |
| 2025-08-11 | ARWR | 17.21 | 20.2 | -323.0 | -0.22 |
| 2025-08-12 | ARWR | 17.79 | 69.8 | -327.1 | -0.31 |
| 2025-08-13 | ARWR | 19.99 | 84.9 | -371.0 | -0.14 |
| 2025-08-14 | ARWR | 18.77 | 84.9 | -80.9 | -0.14 |
| 2025-08-15 | ARWR | 20.50 | 83.7 | -113.4 | -0.15 |
| 2025-08-18 | ARWR | 19.90 | 83.7 | -87.5 | -0.15 |
| 2025-08-19 | ARWR | 19.86 | 84.5 | -93.2 | -0.13 |
| 2025-08-20 | ARWR | 20.22 | 84.5 | -97.5 | -0.13 |
| 2025-08-21 | ARWR | 20.75 | 84.5 | -99.5 | -0.13 |
| 2025-08-22 | ARWR | 21.32 | 84.5 | -99.5 | -0.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | ARWR | -2.11 | 5.40 | 10.78 |
| 2025-07-28 | ARWR | -2.11 | 5.10 | 10.78 |
| 2025-07-29 | ARWR | -2.11 | 5.10 | 10.78 |
| 2025-07-30 | ARWR | -2.11 | 5.10 | 10.78 |
| 2025-07-31 | ARWR | -2.11 | 5.10 | 10.78 |
| 2025-08-01 | ARWR | -2.11 | 5.10 | 10.78 |
| 2025-08-04 | ARWR | -2.11 | 3.58 | 10.78 |
| 2025-08-05 | ARWR | -2.11 | 3.58 | 10.78 |
| 2025-08-06 | ARWR | -2.11 | 3.58 | 10.78 |
| 2025-08-07 | ARWR | -2.11 | 3.58 | 10.78 |
| 2025-08-08 | ARWR | -2.11 | 3.58 | 10.78 |
| 2025-08-11 | ARWR | -2.10 | 4.67 | 10.77 |
| 2025-08-12 | ARWR | -2.10 | 4.67 | 11.22 |
| 2025-08-13 | ARWR | -2.10 | 4.67 | 11.22 |
| 2025-08-14 | ARWR | -2.10 | 4.67 | 11.22 |
| 2025-08-15 | ARWR | -2.10 | 4.67 | 11.22 |
| 2025-08-18 | ARWR | -2.15 | 3.96 | 11.23 |
| 2025-08-19 | ARWR | -2.14 | 3.96 | 11.23 |
| 2025-08-20 | ARWR | -2.14 | 3.96 | 11.23 |
| 2025-08-21 | ARWR | -2.14 | 3.96 | 10.08 |
| 2025-08-22 | ARWR | -4.81 | 3.96 | 10.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.26
Avg. EPS Est. Current Quarter
-0.21
Avg. EPS Est. Next Quarter
-0.41
Insider Transactions
-4.81
Institutional Transactions
3.96
Beta
0.97
Average Sales Estimate Current Quarter
168
Average Sales Estimate Next Quarter
140
Fair Value
Quality Score
31
Growth Score
36
Sentiment Score
66
Actual DrawDown %
77.2
Max Drawdown 5-Year %
-89
Target Price
41.62
P/E
Forward P/E
PEG
P/S
5.15
P/B
5.64
P/Free Cash Flow
EPS
-1.26
Average EPS Est. Cur. Y
-0.13
EPS Next Y. (Est.)
-3.39
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-25.9
Relative Volume
1.28
Return on Equity vs Sector %
-53.1
Return on Equity vs Industry %
-40.2
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.04
EBIT Estimation
-99.5
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading